Adults with Sickle Cell Disease can join a study to test a new drug called **panobinostat**. This drug might help manage symptoms by increasing hemoglobin F, which helps blood cells work better, and reducing inflammation, which can cause pain and sickness. The study will last for 12 weeks and participants must have had issues with or refused hydroxyurea, a usual treatment. This is a Phase I study, meaning it tests safety and dosage.

**Key Points:**

• The study lasts 12 weeks with weekly doses of the drug.
• Participants will have regular check-ups, including physical exams and blood tests.
• Participants must be 18 or older and have certain types of Sickle Cell Disease.

Volunteers will have a screening visit to ensure they meet the study requirements. Follow-up occurs 4 weeks after treatment ends to monitor safety and effects. Participants should be aware of risks and be able to give informed consent before starting. If you are interested, you should consider the commitment needed and discuss with your doctor.